Pelvic organ prolapse occurs when weakened pelvic floor muscles allow one or more pelvic organs — the bladder, uterus, or rectum — to descend into or outside the vaginal canal. Manufacturers promoted transvaginal mesh as a superior repair option over traditional native tissue surgery, but without the rigorous clinical evidence required for a Class III medical device. The FDA's 2019 market withdrawal confirmed that manufacturers never adequately proved the benefit-risk profile of POP mesh.

POP mesh litigation is distinct from stress urinary incontinence (SUI) mesh litigation. POP mesh — which was placed to repair prolapse of the anterior or posterior vaginal wall — was withdrawn from the market entirely. SUI mesh (mid-urethral slings) remains available but carries its own documented risks and active litigation. If you had mesh placed for prolapse repair, your case may be evaluated under the stronger regulatory framework established by the 2019 FDA order.